A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

Leukemia

Volumn 30, Issue 11, 2016, Pages 2133-2141

  Jones, L ^a   Carol, H ^a   Evans, K ^a   Richmond, J ^a   Houghton, P J ^b   Smith, M A ^c   Lock, R B ^a  

^a University of New South Wales Sydney   (Australia)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; DRUG ANTIBODY; NEW DRUG; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN MDM2;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG CONJUGATION; DRUG PROGRAM; GENE TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PEDIATRIC PRECLINICAL TESTING PROGRAM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT; DRUG SCREENING; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; TRENDS;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84981537487     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.192     Document Type: Review

References (110)

1. Ries L, Melbert D, Krapcho M, Mariotto A, Miller B, Feuer E et al. SEER Cancer Statistics Review, 1975-2004. Available at: http://seer. cancer. gov/csr/1975-2004/ (accessed 23 November 2015)
2. Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P et al. New drugs for children and adolescents with cancer: The need for novel development pathways. Lancet Oncol 2013; 14: e117-e124.
3. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D Cancer Incidence and Mortality Worldwide: GLOBOCAN 2008. Available at: http://globocan. iarc. fr (accessed 23 November 2015)
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
5. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer 2014; 120: 2497-2506.
6. Pui C-H. Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc 2010; 109: 777-787.
7. Hirschfeld S, Ho PT, Smith M, Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol 2003; 21: 1066-1073.
8. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010; 28: 648-654.
9. Pui C-H, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nat Rev Clin Oncol 2011; 8: 540-549.
10. National Cancer Institute. Cancer Trends Progress Report 6-2011/2012 Update. Available at: http://progressreport. cancer. gov (accessed 23 November 2015)
11. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002; 8: 3646-3657.
12. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
13. Hutchinson L, Kirk R. High drug attrition rates-where are we going wrong Nat Rev Clin Oncol 2011; 8: 189-190.
14. Houghton PJ. New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer Expert Rev Anticancer Ther 2013; 13: 1135-1138.
15. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004; 40: 837-844.
16. Carol H, Boehm I, Reynolds CP, Kang M, Maris J, Morton C et al. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 2011; 68: 1291-1304.
17. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T et al. Pharmacokineticpharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 2011; 17: 4682-4692.
18. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NLM, Carol H, Boehm I et al. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One 2012; 7: e33894.
19. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R et al. Initial testing (Stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: 783-790.
20. Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res 2014; 20: 4520-4531.
21. Szymanska B, Carol H, Lock RB. Preclinical evaluation. In: Saha V, Kearns P (eds). New Agents for the Treatment of Acute Lymphoblastic Leukemia. Springer: NY, USA, 2011, pp 39-60.
22. Liem NLM, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
23. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R et al. Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: 633-641.
24. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008; 14: 4572-4583.
25. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007; 67: 32-40.
26. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54: 707-715.
27. Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 2004; 22: 829-837.
28. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: A pediatric oncology group study. J Clin Oncol 2002; 20: 1617-1624.
29. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Maris JM et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 992-1000.
30. Vietti T, Nitschke R, Starling K, van Eys J. Evaluation of cis-dichlorodiammineplatinum( II) in children with advanced malignant diseases: Southwest Oncology Group Studies. Cancer Treat Rep 1979; 63: 1611-1614.
31. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1198-1206.
32. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D et al. Initial testing (Stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 59: 749-752.
33. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One 2011; 6: e23108.
34. Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P et al. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the pediatric preclinical testing program. Pediatr Blood Cancer 2015; 62: 65-71.
35. Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R et al. Initial testing (Stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 1255-1263.
36. Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R et al. Initial testing (Stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61: 1493-1496.
37. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP et al. Initial testing (Stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 1329-1337.
38. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R et al. Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 636-639.
39. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Phelps D, Schaiquevich P et al. Initial testing (Stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 594-598.
40. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH et al. Initial testing (Stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61: 158-164.
41. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 59: 185-188.
42. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E et al. Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 200-209.
43. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 2010; 9: 101-112.
44. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H et al. Initial testing (Stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 799-805.
45. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP et al. Initial testing (Stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 37-45.
46. Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R et al. Initial testing (Stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61: 1486-1489.
47. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST et al. Initial testing (Stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 668-677.
48. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST et al. Initial testing (Stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 505-508.
49. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H et al. Initial testing (Stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-1197.
50. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H et al. Initial testing (Stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 2012; 58: 815-818.
51. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST et al. Initial testing (Stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 56: 595-603.
52. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA et al. Initial testing (Stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: E42-E45.
53. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH et al. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 916-923.
54. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R et al. Initial testing (Stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 42-48.
55. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010; 55: 26-34.
56. Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H et al. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer 2009; 53: 509-512.
57. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA et al. Initial testing (Stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: 791-798.
58. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R et al. Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 57: 606-611.
59. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM et al. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 59: 329-332.
60. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R et al. Initial testing (Stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2015; 62: 91-98.
61. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H et al. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 59: 246-253.
62. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST et al. Initial testing (Stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011; 57: 268-274.
63. Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H et al. Initial testing (Stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54: 307-310.
64. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 51: 34-41.
65. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST et al. Initial testing (Stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the pediatric preclinical testing program. Pediatr Blood Cancer 2014; 61: 245-252.
66. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST et al. Initial testing (Stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 59: 1266-1274.
67. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H et al. Initial testing (Stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55: 1126-1133.
68. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL et al. Initial testing (Stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 2012; 58: 191-199.
69. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT et al. Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2012; 59: 518-524.
70. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60: 1325-1332.
71. Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012; 119: 911-923.
72. Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Gotze K et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with alloimmune effects to induce sustained responses. Leukemia 2012; 26: 2353-2359.
73. Razumovskaya E, Masson K, Khan R, Bengtsson S, Rönnstrand L. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. Exp Hematol 2009; 37: 979-989.
74. Kancha RK, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 2007; 35: 1522-1526.
75. Dolai S, Sia KCS, Robbins AK, Zhong L, Heatley SL, Vincent TL et al. Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. Cancer Res 2016; 76: 2766-2777.
76. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015.
77. Suryani S, Bracken LS, Harvey RC, Sia KCS, Carol H, Chen I-M et al. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAKmutated acute lymphoblastic leukemia. Mol Cancer Ther 2015; 14: 364-374.
78. Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G et al. AZD1480: A phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013; 18: 819-820.
79. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194.
80. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013; 17: 61-75.
81. Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51: 219-227.
82. Suryani S, Evans K, Richmond J, Robbins A, Bracken L, Kurmasheva R et al. Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program [abstract]. Cancer Res 2015; 75. Abstract 3276.
83. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-B, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
84. Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104 A in human leukaemia cells. Biochem Pharmacol 2014; 88: 36-45.
85. Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood 2015; 126: 1193-1202.
86. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 2015; 100: 927-934.
87. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné M-C et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations In Leukemia Study Group. J Clin Oncol 2010; 28: 2529-2537.
88. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
89. Mosse YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel BJ et al. Pediatric phase 1 trial and pharmacokinetic study of MLN8237, an investigational oral selective small molecule inhibitor of Aurora kinase A: A Children's Oncology Group Phase
90. Consortium Study. Clin Cancer Res 2012; 18: 6058-6064.
91. Smith M, Kang M, Reynolds P, Lock R, Carol H, Gorlick R et al. Pediatric preclinical testing program (PPTP) evaluation of the p53-MDM2 antagonist MK-8242. Eur J Cancer 2014; 50: 131.
92. Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A et al. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res 2015; 21: 1395-1405.
93. Wada M, Bartram C, Nakamura H, Hachiya M, Chen D, Borenstein J et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993; 82: 3163-3169.
94. Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 3185-3193.
95. Vedi A, Ziegler DS. Antibody therapy for pediatric leukemia. Front Oncol 2014; 4: 82.
96. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008; 8: 1151-1158.
97. Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res 2013; 19: 1795-1805.
98. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013; 161: 117-127.
99. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010; 55: 254-259.
100. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 2012; 120: 285-290.
101. Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M et al. Curaxins: Anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Sci Transl Med 2011; 3: 95ra74.
102. Nathan PC, Wasilewski-Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1065-1082.
103. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
104. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study. Clin Cancer Res 2007; 13: 1516-1522.
105. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28: 3623-3629.
106. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
107. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28: 4919-4925.
108. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009; 6: 259-265.
109. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M et al. Improved early event-free survival with imatinib in Philadelphia chromosomepositive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 2009; 27: 5175-5181.
110. Murphy B, Yin H, Maris JM, Kolb AE, Gorlick R, Reynolds PC et al. Analysis of single mouse tumor response results from the pediatric preclinical testing program (PPTP) [abstract]. Cancer Res 2015; 75: Abstract 1617.